Bizengri Approved to Treat Some Lung, Pancreatic Cancers
Mar 26, 2025 · FDA has approved zenocutuzumab (Bizengri) to treat lung and pancreatic cancers with a rare genetic alteration called an NRG1 fusion.
Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in
Dec 8, 2025 · Results were presented in a late-breaking oral session at the IASLC-ASCO North America Conference on Lung Cancer (NACLC), in Chicago, Illinois. The new analysis evaluated the efficacy …
FDA grants accelerated approval to zenocutuzumab-zbco
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC …
Aug 14, 2025 · Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Can Partner Therapeutics’ zenocutuzumab-zbco deliver a first-line
Dec 7, 2025 · What are the key takeaways from the updated eNRGy trial results for zenocutuzumab in NRG1+ lung cancer? The latest analysis of Partner Therapeutics’ Phase 2 eNRGy trial reinforces the …
FDA Approves First and Only Systemic Therapy for NRG1+ Lung, …
Dec 4, 2024 · Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma (PDAC) harboring an NRG1 gene …
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers With NRG1 …
Feb 6, 2025 · The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene …
What the FDA Approval of Bizengri Means for Patients With NRG1-Positive …
Mar 6, 2025 · The Food and Drug Administration (FDA) has granted its first approval for a systemic therapy for patients with non-small cell lung cancer (NSCLC) with an Neuregulin 1 (NRG1) gene …
Zenocutuzumab Wins FDA Breakthrough Therapy Designation for
Jul 7, 2023 · The FDA has granted breakthrough therapy designation to zenocutuzumab for use as a potential therapeutic option in patients with advanced unresectable or metastatic, NRG1 …
Accelerated approval for drug targeting NRG1 - Lung Cancer Research ...
Jan 14, 2025 · The good news The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with advanced, unresectable, or …